Dopaminergic Therapies May Decrease Risk of Early and Intermediate Non-exudative Age-related Macular Degeneration Progression.

IF 0.9 4区医学 Q4 OPHTHALMOLOGY

Ophthalmic surgery, lasers & imaging retina Pub Date : 2025-04-18 DOI:10.3928/23258160-20250326-02

Richard A Morgan, Peter J Weng, Sandra S Stinnett, Dilraj S Grewal, Sharon Fekrat

{"title":"Dopaminergic Therapies May Decrease Risk of Early and Intermediate Non-exudative Age-related Macular Degeneration Progression.","authors":"Richard A Morgan, Peter J Weng, Sandra S Stinnett, Dilraj S Grewal, Sharon Fekrat","doi":"10.3928/23258160-20250326-02","DOIUrl":null,"url":null,"abstract":"Background and objective: Age-related macular degeneration (AMD) is a leading cause of vision loss, with progression to geographic atrophy (GA) posing a significant challenge. This study aimed to assess whether dopaminergic therapies (DMTs) reduce risk of AMD progressing to GA.Patients and methods: A retrospective cohort study analyzed electronic health records of 320 patients (449 eyes) with early or intermediate nonexudative AMD at Duke Eye Center from 2014 to 2024. Of these, 80 patients (110 eyes) were on DMTs, and 240 (339 eyes) served as controls. GA progression was evaluated annually over 5 years.Results: GA progression was lower in the DMT group across all intervals, with lifetime rates of 9.4% in the non-DMT group versus 2.7% in the DMT group (P < 0.05). Multivariate analysis showed a significant protective effect (odds ratio 0.08, P < 0.001).Conclusion: DMTs may significantly reduce risk of AMD progressing to GA, warranting further research. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"1-6"},"PeriodicalIF":0.9000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20250326-02","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Age-related macular degeneration (AMD) is a leading cause of vision loss, with progression to geographic atrophy (GA) posing a significant challenge. This study aimed to assess whether dopaminergic therapies (DMTs) reduce risk of AMD progressing to GA.

Patients and methods: A retrospective cohort study analyzed electronic health records of 320 patients (449 eyes) with early or intermediate nonexudative AMD at Duke Eye Center from 2014 to 2024. Of these, 80 patients (110 eyes) were on DMTs, and 240 (339 eyes) served as controls. GA progression was evaluated annually over 5 years.

Results: GA progression was lower in the DMT group across all intervals, with lifetime rates of 9.4% in the non-DMT group versus 2.7% in the DMT group (P < 0.05). Multivariate analysis showed a significant protective effect (odds ratio 0.08, P < 0.001).

Conclusion: DMTs may significantly reduce risk of AMD progressing to GA, warranting further research. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].

查看原文本刊更多论文

多巴胺能治疗可降低早期和中期非渗出性年龄相关性黄斑变性进展的风险。

背景与目的：年龄相关性黄斑变性（AMD）是导致视力丧失的主要原因，其进展为地理萎缩（GA）提出了重大挑战。本研究旨在评估多巴胺能疗法（dmt）是否能降低AMD进展为GA的风险。患者和方法：一项回顾性队列研究分析了2014年至2024年杜克眼科中心320例早期或中期非渗出性AMD患者（449只眼睛）的电子健康记录。其中，80名患者（110只眼睛）接受dmt治疗，240名患者（339只眼睛）作为对照组。在5年内每年评估GA进展情况。结果：DMT组GA进展在所有时间间隔内都较低，非DMT组的终生发生率为9.4%，而DMT组为2.7% （P < 0.05）。多因素分析显示有显著的保护作用（优势比0.08,P < 0.001）。结论：dmt可显著降低AMD发展为GA的风险，值得进一步研究。[眼科外科激光成像视网膜2025；56:XX-XX]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic surgery, lasers & imaging retina OPHTHALMOLOGY-SURGERY

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.